1. Market Research
  2. > Biotechnology Market Trends
  3. > Shenzhen Beike Biotechnology Co., Ltd. - Product Pipeline Review - 2013

Shenzhen Beike Biotechnology Co., Ltd. - Product Pipeline Review - 2013

Summary

Global Markets Direct’s pharmaceuticals report, “Shenzhen Beike Biotechnology Co., Ltd. - Product Pipeline Review - 2013” provides data on the Shenzhen Beike Biotechnology Co., Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Shenzhen Beike Biotechnology Co., Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Shenzhen Beike Biotechnology Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Shenzhen Beike Biotechnology Co., Ltd. - Brief Shenzhen Beike Biotechnology Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Shenzhen Beike Biotechnology Co., Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Shenzhen Beike Biotechnology Co., Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Shenzhen Beike Biotechnology Co., Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Shenzhen Beike Biotechnology Co., Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Shenzhen Beike Biotechnology Co., Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Shenzhen Beike Biotechnology Co., Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Shenzhen Beike Biotechnology Co., Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Shenzhen Beike Biotechnology Co., Ltd. and identify potential opportunities in those areas.

Table Of Contents

Shenzhen Beike Biotechnology Co., Ltd. - Product Pipeline Review - 2013
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Shenzhen Beike Biotechnology Co., Ltd. Snapshot 4
Shenzhen Beike Biotechnology Co., Ltd. Overview 4
Key Information 4
Key Facts 4
Shenzhen Beike Biotechnology Co., Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Pipeline Products - Combination Treatment Modalities 9
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline Products Glance 10
Shenzhen Beike Biotechnology Co., Ltd. Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Shenzhen Beike Biotechnology Co., Ltd. - Drug Profiles 11
NU-211-01 + NC-215-01 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
NU-211-01 + NU-215-02 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
NU-215-01 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline Analysis 14
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline Products by Therapeutic Class 14
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline Products by Route of Administration 16
Shenzhen Beike Biotechnology Co., Ltd. - Dormant Projects 17
Shenzhen Beike Biotechnology Co., Ltd. - Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables

Shenzhen Beike Biotechnology Co., Ltd., Key Information 4
Shenzhen Beike Biotechnology Co., Ltd., Key Facts 4
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline by Indication, 2013 6
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2013 7
Shenzhen Beike Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
Shenzhen Beike Biotechnology Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 9
Shenzhen Beike Biotechnology Co., Ltd. - Phase I, 2013 10
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline By Therapeutic Class, 2013 15
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline By Route of Administration, 2013 16
Shenzhen Beike Biotechnology Co., Ltd. - Dormant Developmental Projects,2013 17

List of Figures

Shenzhen Beike Biotechnology Co., Ltd. - Pipeline by Indication, 2013 6
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline by Stage of Development, 2013 7
Shenzhen Beike Biotechnology Co., Ltd. - Monotherapy Products in Pipeline, 2013 8
Shenzhen Beike Biotechnology Co., Ltd. - Combination Treatment Modalities in Pipeline, 2013 9
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline By Therapeutic Class, 2013 14
Shenzhen Beike Biotechnology Co., Ltd. - Pipeline By Route of Administration, 2013 16

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • July 2016
  • by Global Markets Direct

Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Interleukin 1 Beta (IL 1 Beta or Catabolin or IL1B) - Pipeline Review, H2 2016’, ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.